- Home
- Companies
- BioLingus AG
- Articles
- Project - Sublingual Dual Incretin ...
Project - Sublingual Dual Incretin Inhibitor (GLP-1/GIP)
Courtesy of BioLingus AG
Biolingus explores the development of a sublingual dual incretin inhibitor.
BioLingus will position these products in the “epidemic” markets of obesity and type II diabetes :
- More than 400 MM people suffer from diabetes today. The global type 2 diabetes market is expected to grow to $58.7 billion by 2025, with an annual growth rate of 6.5%, according to research and consulting firm GlobalData.
- According to WHO, more than 1.9 billion adults, 18 years and older, were overweight. Of these, over 600 million were obese. The global obesity treatment market is expected to reach USD 15.6 billion by 2024, according to a new report by Grand View Research.
Within this huge market, the market-segment for incretin analogues in diabetes and obesity is estimated at 12 Billion USD. Furthermore, it is expected that this market will further grow with new metabolic indications such as NASH and pre-diabetes. The sublingual liraglutide/semaglutide will be positioned in high priced/reimbursed markets while the SL exenatide will be positioned in lower cost/emerging markets where affordability and access are critical.
-
Most popular related searches
Customer comments
No comments were found for Project - Sublingual Dual Incretin Inhibitor (GLP-1/GIP). Be the first to comment!